Local ablative treatment for oligoprogression during immunotherapy in metastatic non-small-cell lung cancer: a systematic review and meta-analysis.
Ismaell Massalha, Adham Hijab, Reem Zabit et al.
✦ AI-curated · Sources linked
In 30 seconds
This PRISMA-compliant systematic review and meta-analysis assessed local ablative treatment (LAT), with continuation of the same immune checkpoint inhibitor, for oligoprogressive or oligo-resistant metastatic NSCLC during active immunotherapy. Twenty-two studies entered the qualitative synthesis; four studies contributed to each primary analysis. LAT-oriented management was associated with longer progression-free survival (pooled HR 0.45, 95% CI 0.33-0.62) and overall survival (pooled HR 0.41, 95% CI 0.27-0.63). The authors characterize the evidence as low certainty and predominantly observational, with no NSCLC-specific randomized trials.
Key findings
- LAT-oriented management was associated with improved progression-free survival (pooled HR 0.45, 95% CI 0.33-0.62; 95% PI 0.28-0.74; I 2 = 0%).
- Overall survival was also associated with LAT-oriented management (pooled HR 0.41, 95% CI 0.27-0.63; 95% PI 0.24-0.69; I 2 = 0%).
- The qualitative synthesis included 22 studies, while four studies contributed to each primary analysis.
Why it matters
Focal progression during otherwise effective immunotherapy may not always indicate systemic treatment failure. The pooled associations suggest that ablating limited progressing disease while continuing the same immunotherapy could help preserve disease control in selected patients. However, the evidence base is low certainty and largely observational, so the findings support consideration rather than a definitive treatment strategy.
What to keep in mind
Evidence was predominantly observational and of low certainty; the abstract notes the absence of NSCLC-specific randomized trials.